Is Eovist Suitable for Arterial-Phase MR Imaging of Liver

Status Completed

Clinical Trial Summary

To examine the quality of liver images produced when the contrast agent Eovist is used during MRI.

Clinical Trial Description

Researchers will review data from the Eovist MRI and compare the scan with previous MRI exams the patient had with the same or other contrast agents.

To determine the efficacy of Eovist contrast agent in producing MRI images of the liver. We will monitor patients for any unusual symptoms (adverse events) when the contrast is given.

Patients are asked to hold their breath during an MRI scan. Eovist may interfere with the "breath hold" which could result in more breathing artifacts (based on a qualitative scale) on arterial images when the patients are given Eovist vs. other contrast agents. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02684526
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	December 2011
Completion date	October 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798861` - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed	`NCT01968395` - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure	Phase 4
Completed	`NCT01437969` - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting	`NCT00155376` - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography	Phase 4
Recruiting	`NCT00172705` - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique	N/A
Completed	`NCT04185454` - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese	N/A
Completed	`NCT02506335` - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease	Early Phase 1
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed	`NCT02306018` - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation	N/A
Completed	`NCT01988753` - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed	`NCT01970904` - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients	N/A
Terminated	`NCT00741117` - Conjugated Hyperbilirubinemia and Pulse Oximetry	N/A
Enrolling by invitation	`NCT01483248` - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00074386` - Kidney and Liver Transplantation in People With HIV	N/A
Completed	`NCT00245830` - Ischemic Preconditioning of Liver in Cadaver Donors	N/A
Completed	`NCT02329821` - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection	N/A
Completed	`NCT01303549` - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Phase 4
Completed	`NCT01650181` - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis	Phase 4
Completed	`NCT00799851` - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices	Phase 4
Completed	`NCT00058890` - Gabapentin to Treat Itch in Patients With Liver Disease	Phase 3